Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof of concept ctDNA-guided treatment in HR-positive/HER2-negative early breast cancer
2022-002616-24Phase 2Active
- Sponsor
- Medica Scientia Innovation Research, S.L. (MEDSIR)
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of giredestrant, inavolisib and abemaciclib in breast cancer (3 arms), sponsored by Medica Scientia Innovation Research, S.L. (MEDSIR). Primary endpoint: Proportion of patients with ≥90% decrease or clearance in baseline ctDNA at 3 months. Started Jan 2023; status: active.
02
Drugs
giredestrantinavolisibabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-002616-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002616-24.